Research
Hormonal
Visceral obesity is a critical risk factor for cardiovascular disease, often present in individuals with normal BMI, leading to underestimation of cardiovascular risk in clinical practice.
Don't rely solely on BMI. If you have a family history of heart disease, ask for a waist circumference measurement or visceral fat assessment, as 'normal weight' obesity can still cause heart attacks.
GoodQualifiesHIGH confidence
A critical risk factor for CVD is the presence of visceral obesity in cases of overweight and sometimes even normal weight. This phenotype is often overlooked in clinical settings not focused on obesity, leading to a significant underestimation of cardiovascular risk in clinical practice.
Why this rating
Based on established pathophysiological mechanisms and epidemiological data cited.
Source
La medicina cardiometabolica nell’obesità
-Aggiornamento Dalla Letteratura et al. · il Diabete · 2024
DOI 10.30682/ildia2304d
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly subcutaneous Semaglutide 2.4 mg significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight or obesity, primarily by reducing non-fatal myocardial infarction.Strong
- Bariatric surgery (RYGB, Sleeve Gastrectomy) significantly reduces long-term cardiovascular mortality and incidence of coronary heart disease, stroke, and myocardial infarction compared to non-surgical management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →